Journal of the American Medical Association (JAMA) Publishes Pivotal Phase 3 Data for Optune Plus Temozolomide to Treat Newly Diagnosed Glioblastoma

Data show Optune plus standard of care temozolomide extended overall survival and progression-free survival of newly diagnosed glioblastoma patients compared to temozolomide alone ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) announced today that data from the pivotal phase 3 clinical trial of Optune in combination with temozolomide for the treatment of newly diagnosed glioblastoma (GBM) have …

Novocure to Hold Webcast to Discuss JAMA Publication of EF-14 Phase 3 Clinical Trial Data

ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) will hold a webcast today at 5 p.m. EST to discuss the publication of the EF-14 phase 3 clinical trial results in the Journal of the American Medical Association (JAMA). The EF-14 trial data show that treatment with Optune plus standard of care temozolomide significantly extended both progression-free survival …

New Data on Tumor Treating Fields’ Anti-Mitotic Mechanism of Action Published in Scientific Reports

Tumor Treating Fields disrupt mitotic spindle formation leading to irregular chromosome segregation and mitotic catastrophe in cancer cells ST. HELIER, Jersey–(BUSINESS WIRE)–New preclinical data on Novocure’s (NASDAQ: NVCR) Tumor Treating Fields (TTFields) therapy revealed a more thorough understanding of how the therapy works at a cellular level. As an anti-mitotic treatment, TTFields interfere with cancer …

Retrospective Analysis Shows Optune Safe in Glioblastoma Patients with Implanted Non-Programmable Shunts

Removal of FDA contraindication increases addressable GBM patient population ST. HELIER, Jersey–(BUSINESS WIRE)–A retrospective analysis of Novocure’s (NASDAQ: NVCR) Tumor Treating Fields (TTFields) therapy shows that TTFields therapy is safe in adult glioblastoma patients with implanted non-programmable shunts. The data were presented on Nov. 20 at the 20th Annual Society for Neuro-Oncology Meeting in San …

Preliminary Phase 2 Data Demonstrate Tumor Treating Fields is Safe in Patients with Brain Metastases Originating from Non-Small Cell Lung Cancer

ST. HELIER, Jersey–(BUSINESS WIRE)–Preliminary data from COMET, a phase 2 randomized trial sponsored by Novocure (NASDAQ: NVCR), show that the use of Tumor Treating Fields (TTFields) therapy is safe in the treatment of brain metastases originating from non-small cell lung cancer (NSCLC). The results of a preliminary analysis of the ongoing European study were presented …